Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Sherlock Biosciences, a US-based home diagnostics technology developer exploiting Harvard University research, has received $80m in series B funding from a consortium led by Novalis LifeSciences. The round featured Illumina Ventures, the venture capital fund backed by genomics technology producer Illumina, as well as Albany Capital, Catalio Capital Management and existing investors including Northpond Ventures…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Talking Tech Transfer interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
